ENERGEN and PUNCTUA devices are designed to improve the ability of physicians to deliver effective patient care," said Hank Kucheman, Executive Vice President and Group President, Cardiology, Rhythm and Vascular for Boston Scientific. "This new portfolio of products, built on our tradition of innovation, continues our advantages in size, shape and longevity and provides multiple therapy options to match specific patient needs."
The Company received CE Mark approval for its ENERGEN and PUNCTUA CRT-Ds and ICDs in October 2010. In the U.S., they are investigational devices, limited by applicable law to investigational use and not available for sale. The Company expects Food and Drug Administration approval for the devices in late 2011 or early 2012.
About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals and compliance, clinical trials, product features and performance, technology and competitive offerings. If our underlying ass
Page: 1 2 3 4 Related medicine technology :1
|SOURCE Boston Scientific Corporation|
Copyright©2010 PR Newswire.
All rights reserved
. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA2
. Boston Scientific Announces Schedule for European Society of Cardiology Congress 20073
. Boston University Biomedical Engineers Find Chink in Bacterias Armor4
. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 20075
. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis6
. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures7
. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions8
. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial9
. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results10
. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day11
. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death